Universitätsklinikum Frankfurt
Welcome,         Profile    Billing    Logout  
 1 Trial 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sebastian, Martin
ANTELOPE, NCT05689671: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Recruiting
4
136
Europe
Atezolizumab, Tecentriq, Nab paclitaxel, Abraxane, Carboplatin, Pembrolizumab, Keytruda, Cisplatin, Pemetrexed
Nikolaj Frost MD, Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Non-Small Cell Lung Cancer Metastatic
10/25
10/26
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
NCT04471415 / 2020-002770-27: Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Terminated
2a
61
Europe, US, RoW
DRP-104, atezolizumab
Dracen Pharmaceuticals, Inc., Dracen Pharmaceuticals, Inc.
Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
03/23
03/23
FIND, NCT03827850 / 2018-000399-13: FGFR Inhibitor in FGFR Dysregulated Cancer

Terminated
2
22
Europe
ERDAFITINIB, JNJ -42756493, WHO NUMBER 10147
Lung Cancer Group Cologne
Lung Cancer, NSCLC, Pulmonary Neoplasm, Squamous Cell Lung Cancer, NSCLC Stage IV
09/22
10/22
PrevTel, NCT05322889: Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy

Completed
2
35
Europe
Telmisartan tablets
Dr. Frank Behrens, Johann Wolfgang Goethe University Hospital
Neuropathic Pain, Chemotherapy Effect
10/22
06/23
PACE-LUNG, NCT05281406 / 2019-004757-88: Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment

Recruiting
2
50
Europe
Osimertinib, Tagrisso, Pemetrexed, Cisplatin, Carboplatin
Goethe University
NSCLC Stage IIIB, NSCLC Stage IV
11/23
11/26
PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting
1/2
73
Europe
PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed
PDC*line Pharma SAS
Non Small Cell Lung Cancer
07/24
12/25
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
03/26
07/26
NCT06638307: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Recruiting
1
124
Europe, US, RoW
MEN2312, Elacestrant
Stemline Therapeutics, Inc.
Advanced Breast Cancer
10/25
10/26

Download Options